Dialysis solution having at least one osmotic agent
11090388 · 2021-08-17
Assignee
- FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (Bad Homburg, DE)
- FRIEDRICH-SCHILLER-UNIVERSITAET JENA (Jena, DE)
Inventors
- Thomas Heinze (Jena, DE)
- Robert Hampe (Jena, DE)
- Robert BERLICH (St. Wendel, DE)
- Lisa Finkler (Nonnweiler, DE)
- Jens Lothar Burkhart (St. Ingbert, DE)
Cpc classification
A61K31/205
HUMAN NECESSITIES
A61K36/47
HUMAN NECESSITIES
A61K45/06
HUMAN NECESSITIES
A61K31/185
HUMAN NECESSITIES
A61K31/718
HUMAN NECESSITIES
A61K36/47
HUMAN NECESSITIES
A61K31/718
HUMAN NECESSITIES
A61K31/205
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
A61K31/185
HUMAN NECESSITIES
A61K47/36
HUMAN NECESSITIES
International classification
A61K31/718
HUMAN NECESSITIES
A61K31/205
HUMAN NECESSITIES
A61K36/47
HUMAN NECESSITIES
A61K45/06
HUMAN NECESSITIES
A61K47/36
HUMAN NECESSITIES
Abstract
The invention relates to a dialysis solution having at least one osmotic agent, with the osmotic agent being a polysaccharide modified by 2-sulfoethyl groups.
Claims
1. A dialysis solution having at least one osmotic agent, characterized in that the osmotic agent is a modified polysaccharide, wherein the modified polysaccharide is a 2-sulfoethyl starch, characterized in that the starch underlying the 2-sulfoethyl starch is a starch that was reduced with NaBH.sub.4 before the sulfoethylation, and wherein the molar mass of the unmodified sulfoethyl starch is between 1,000 and 20,000 g/mol.
2. A dialysis solution in accordance with claim 1, characterized in that the modified polysaccharide has a degree of substitution between 0.05 and 1.0.
3. A dialysis solution in accordance with claim 1, characterized in that the dialysis solution does not contain any further osmotic agent in addition to the modified polysaccharide.
4. A dialysis solution in accordance with claim 1, characterized in that the dialysis solution furthermore has electrolytes and a buffer system.
5. A dialysis solution in accordance with claim 4, characterized in that the electrolytes are selected from the group consisting of sodium ions, potassium ions, calcium ions, magnesium ions, chloride ions, and combinations thereof.
6. A dialysis solution in accordance with claim 4, characterized in that the buffer system is a lactate buffer, a hydrogen carbonate buffer, or a combination thereof.
7. A dialysis solution in accordance with claim 4, characterized in that the electrolytes, where present and independently of one another, are present in the following concentrations in the dialysis solution (figures in mmol/l): TABLE-US-00002 Sodium ions 125-150 Potassium ions .sup. 0-4.5 Calcium ions .sup. 0-2.5 Magnesium ions 0-5 Chloride ions 90-120 Lactate/Lactic acid/(Hydrogen) carbonate/CO.sub.2 30-60.
8. A dialysis solution in accordance with claim 1, characterized in that the pH of the dialysis solution is between 5.0 and 8.0.
9. A dialysis solution in accordance with claim 1 for use in peritoneal dialysis.
10. A dialysis solution in accordance with claim 1, characterized in that the modified polysaccharide has a degree of substitution between 0.2 and 0.5.
11. A dialysis solution in accordance with claim 1, characterized in that the dialysis solution comprises mixtures of the modified polysaccharide and further osmotic agents.
12. A dialysis solution in accordance with claim 1, characterized in that the dialysis solution comprises mixtures of the modified polysaccharide and (i) carnitine or (ii) taurine.
13. A dialysis solution in accordance with claim 1, characterized in that the pH of the dialysis solution is between 5.5 and 6.5.
14. A dialysis solution in accordance with claim 1, characterized in that the pH of the dialysis solution is between 6.5 and 7.5.
15. A method of preparing an osmotic agent of a dialysis solution in accordance with claim 1 comprising modification of a polysaccharide starch by 2-sulfoethyl groups.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13) A dialysis solution L1 containing an osmotic agent is located in the interior of the tube 10. The tube 10 is located in a solution L2 which has the same composition as the solution L1 in the tube 10 with the sole difference that the solution L2 does not have any osmotic agent.
(14)
(15)
(16) As can be seen from a comparison of the illustrations of
(17)
(18) Reference numerals 3 and 4 relate to solutions having 5% (w/v) glucose (solution 4) and having 5% (w/v) icodextrin (solution 3).
(19) A further evaluation of the osmotic effect of known osmotic agents and of osmotic agents in accordance with the invention is shown in
(20) The experimental conditions were identical for both
(21) Reference symbol A shows the result for the use of 5% (w/v) glucose and illustrates the fact that a volume increase by 10% has taken place after a 24-hour dwell time. Reference symbol B shows the result for the use of a 5% (w/v) icodextrin solution, with a volume increase of 40% having taken place after a 24-hour dwell time. Reference symbol C shows the result for the use of 5% (w/v) tapioca starch (Mn=3321 g/mol), with a volume increase of a good 50% having taken place after a 24-hour dwell time.
(22) Reference symbols D and E show the result for dialysis solutions in accordance with the present invention, with 5% w/v) 2-sulfoethyl starch being used as the only osmotic agent having an average degree of substitution DS of 0.46 (E) and 0.20 (D), each prepared from tapioca starch (numerically mean molar mass, Mn=3321 g/mol) as described in connection with
(23) It becomes clear from
(24) The experimental conditions for the results in accordance with
(25) This filled tube was stored while being moved at a temperature of 38° C. in a bath of the same experiment solution, but without an osmotic agent, for 24 hours.
(26) The volume increase of the filling volume of the tube reflecting the osmotic effect of the agent was determined at different times. As can be seen from
(27)
(28) In contrast, the final values after 24 h for icodextrin were at a good 40% and those of glucose at approximately 10%.
(29) The osmotic agents in accordance with the invention not only show an increased ultrafiltration efficiency after 24 hours, but also a higher value with small dwell times with respect to icodextrin.
(30) While the volume increase with icodextrin has a substantially linear progression, a comparatively steep increase can be seen with the dialysis solutions containing 2-sulfoethyl starch, said steep increase bottoming out at higher dwell times and merging into a substantially linear progression.
(31) The increase of the tube volume at low dwell times is comparable with that of glucose on the use of 2-sulfoethyl starch. At higher values, however, the volume increase with glucose as the osmotic agent is much smaller and remains constant after a dwell time of approximately three hours, as can be seen from
(32) Some embodiments for carrying out the invention will be described in the following:
EXAMPLE 1
(33) 40.0 g degraded tapioca starch (
EXAMPLE 2
(34) In accordance with Example 1, 40.0 g degraded tapioca starch (
(35) DS (determined by means of elementary analysis): 0.20.
EXAMPLE 3
(36) In accordance with Example 1, 40.0 g degraded tapioca starch (
(37) DS (determined by means of elementary analysis): 0.68.
EXAMPLE 4
(38) 30.0 g degraded tapioca starch (
(39) In accordance with Example 2, 25.0 g of the starch treated with sodium boron hydride is converted and isolated with a total of 40 g 25% (w/w) aqueous sodium vinyl sulfonate solution (0.5 mol/mol AGE) and 4.63 g NaOH. .sup.1H and .sup.13C NMR spectra confirm the structure (
(40) DS (determined by means of elementary analysis): 0.09.